Innoveren Scientific Inc (IVRN)

[236T568]

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On May 17, 2017, Medovex Corp. (the “Company”) received a letter from the Listing Qualifications Department of the NASDAQ Stock Market (the “Staff”) notifying the Company that the stockholders’ equity of $1,895,299 as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 was below the minimum stockholders’ equity of $2,500,000 required for continued listing on the NASDAQ Capital Market as set forth in NASDAQ listing rule 5550(b)(1) (the “Rule”).

The Company has the right to request an appeal of this determination by May 24, 2017 or its common stock will be suspended at the opening of business on May 26, 2017. The Company intends to request an appeal of the determination within the required time period. There can be no assurance that the appeal will be granted.







SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



MEDOVEX CORP.


Date: May 23, 2017
By: /s/ Jarrett Gorlin
Jarrett Gorlin
Chief Executive Officer

http://ih.advfn.com/p.php?pid=nmona&article=74678554&symbol=MDVX